Johnson & Johnson Receives FDA Approval for Alhemo in Hemolytic Disease of the Fetus and Newborn

Johnson & Johnson today announced that the FDA has approved nipocalimab (Alhemo) for the prevention of hemolytic disease of the fetus and newborn (HDFN) in pregnant individuals who are at high risk. HDFN is a serious condition where maternal antibodies cross the placenta and destroy fetal red blood cells. Nipocalimab is an anti-FcRn antibody that reduces maternal IgG antibody levels, including the pathogenic antibodies that cause HDFN. In the Phase 2/3 UNITY trial, nipocalimab significantly reduced the need for intrauterine transfusions and improved fetal outcomes. This approval represents a significant advancement in the management of high-risk pregnancies complicated by HDFN.